Adial Pharmaceuticals (ADIL) Enterprise Value (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Enterprise Value of -$4.6 million for Q1 2026, up 22.06% sequentially from -$5.9 million in Q4 2025, and down 93.77% YoY from -$73.5 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Enterprise Value (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Enterprise Value for 10 years, with the latest figure at -$4.6 million in Q1 2026.
- Quarterly Enterprise Value fell 93.77% year-over-year to -$4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.6 million (down 93.77% YoY) and the FY2025 annual result came in at -$5.9 million, down 56.81% from the prior year.
- Enterprise Value advanced to -$4.6 million in Q1 2026 per ADIL's latest filing, from -$5.9 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$315880.0 in Q3 2023 and troughed at -$12.7 million in Q1 2022.
- A 5-year average of -$4.6 million and a median of -$4.6 million in 2026 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value surged 94.51% in 2023, then tumbled 1547.57% in 2024.
- Over 5 years, Enterprise Value stood at -$4.0 million in 2022, then gained by 29.35% to -$2.8 million in 2023, then tumbled by 32.66% to -$3.8 million in 2024, then tumbled by 56.81% to -$5.9 million in 2025, then climbed by 22.06% to -$4.6 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$4.6 million, -$5.9 million, and -$4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | -28.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.58 Mn |
| Dec 31, 2025 | -5.88 Mn |
| Sep 30, 2025 | -4.61 Mn |
| Jun 30, 2025 | -5.91 Mn |
| Mar 31, 2025 | -2.37 Mn |
| Dec 31, 2024 | -3.75 Mn |
| Sep 30, 2024 | -5.20 Mn |
| Jun 30, 2024 | -3.29 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -2.83 Mn |
| Sep 30, 2023 | -315,880.00 |
| Jun 30, 2023 | -1.22 Mn |
| Mar 31, 2023 | -2.31 Mn |
| Dec 31, 2022 | -4.00 Mn |
| Sep 30, 2022 | -5.75 Mn |
| Jun 30, 2022 | -9.16 Mn |
| Mar 31, 2022 | -12.69 Mn |
| Dec 31, 2021 | -6.06 Mn |
| Sep 30, 2021 | -7.18 Mn |
| Jun 30, 2021 | -5.21 Mn |